Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
ImmunityBio (NASDAQ:IBRX) Director Sells $187,750.00 in Stock
05:23am, Saturday, 24'th Jan 2026
ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) Director Christobel Selecky sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at a
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month
05:41pm, Friday, 23'rd Jan 2026
Expand NASDAQ: IBRX ImmunityBio Today's Change (-12.13%) $-0.89 Current Price $6.45 Key Data Points Market Cap $7.2B Day's Range $6.43 - $7.88 52wk Range $1.83 - $8.28 Volume 75M Avg Vol 22M Gross Mar
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence,
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
05:38pm, Wednesday, 21'st Jan 2026
Expand NASDAQ: IBRX ImmunityBio Today's Change (6.79%) $0.44 Current Price $6.92 Key Data Points Market Cap $6.4B Day's Range $5.71 - $7.10 52wk Range $1.83 - $7.98 Volume 96M Avg Vol 19M Gross Margin
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
11:50am, Wednesday, 21'st Jan 2026
IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer
05:47pm, Tuesday, 20'th Jan 2026
Expand NASDAQ: IBRX ImmunityBio Today's Change (17.39%) $0.96 Current Price $6.48 Key Data Points Market Cap $5.4B Day's Range $6.08 - $7.98 52wk Range $1.83 - $7.98 Volume 210M Avg Vol 16M Gross Marg
FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer
01:47pm, Tuesday, 20'th Jan 2026
ImmunityBio Inc. (NASDAQ: IBRX) on Tuesday said it plans to submit additional information to the U.S. Food and Drug Administration (FDA) within 30 days following a Type B end-of-phase meeting related
Wealth Management Associates, Inc. Buys 19,000 Shares of ImmunityBio Inc (IBRX)
09:08am, Tuesday, 20'th Jan 2026
Summary Wealth Management Associates, Inc. initiated a new position in ImmunityBio Inc(IBRX), purchasing 19,000 shares valued at approximately $37,620
Top 3 Health Care Stocks You May Want To Dump In January
08:46am, Tuesday, 20'th Jan 2026
As of Jan. 20, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA re
ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results
11:40am, Monday, 19'th Jan 2026
IBRX shares surge after updated data from the study of CD19 t-haNK show durable complete responses in Waldenstrom lymphoma without chemo or lymphodepletion.
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year
04:57pm, Friday, 16'th Jan 2026
Explosive Anktiva sales, new cancer data, and fresh approvals are rapidly redefining this immunotherapy story, today, Jan. 16, 2026.
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:45pm, Friday, 16'th Jan 2026
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Why ImmunityBio Stock Is Skyrocketing Again Today
01:45pm, Friday, 16'th Jan 2026
ImmunityBio announced this morning that it had reached a major enrollment threshold for one of its clinical trials. It also highlighted initial success in treating patients with Non-Hodgkin lymphoma w
ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline
12:52pm, Friday, 16'th Jan 2026
ImmunityBio Inc. (NASDAQ: IBRX) stock has surged more than 100% year to date after the upbeat fourth-quarter preliminary results and trial data.
